2016
Drug interactions between buprenorphine, methadone and hepatitis C therapeutics
Ogbuagu O, Friedland G, Bruce RD. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics. Expert Opinion On Drug Metabolism & Toxicology 2016, 12: 721-731. PMID: 27140427, DOI: 10.1080/17425255.2016.1183644.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsDirect acting antiviralsOpioid use disorderDrug interactionsUse disordersHCV direct acting antiviralsNovel direct acting antiviralsHepatitis C virus infectionHepatitis C therapeuticsHigh HCV prevalenceC virus infectionMedication-assisted therapyPharmacodynamic drug interactionsSpecific drug combinationsDrug package insertsHCV prevalenceHCV infectionHCV treatmentOpioid withdrawalActing antiviralsCombination regimenPharmacodynamic assessmentConcurrent administrationDrug levelsHigh prevalenceVirus infection
1992
Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection.
Schwartz E, Brechbühl A, Kahl P, Miller M, Selwyn P, Friedland G. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. JAIDS Journal Of Acquired Immune Deficiency Syndromes 1992, 5: 619-26. PMID: 1588496.Peer-Reviewed Original ResearchConceptsIntravenous drug usersControl patientsMethadone patientsPharmacokinetic parametersHigh-pressure liquid chromatographyFormer intravenous drug usersIntravenous drug-using patientsMethadone maintenance therapyDrug-using patientsConcentration-time curveHuman hepatic microsomesZDV levelsZDV therapyZDV treatmentMaintenance therapyMethadone concentrationsMethadone groupHIV infectionPharmacokinetic interactionsSerum levelsConcurrent administrationIVDU patientsUrinary excretionPatientsZidovudine